➡️ FDAapproves a new immunotherapy combination for use in the treatment of unresectable HCC, the most common type of liver cancer. Single dose of Tremelimumab then Regular Interval Durvalumab. STRIDE MedTwitter
The US Food and Drug Administration has approved a new immunotherapy combination for use in the treatment of unresectableThe new combination comprises a single dose of tremelimumab followed by treatment withThis marks the first worldwide approval for tremelumumab, which is a CTLA-4 antibody.
Results from this trial showed that 30% of patients treated with that combination were still alive at 3 years, compared to 20% of patients who were treated with the standard regimen,"In addition to this regimen demonstrating a favorable 3-year survival rate in the HIMALAYA trial, safety data showed no increase in severe liver toxicity or bleeding risk for the combination, important factors for patients with liver cancer who also have advanced liver disease," commented the principal...
He also made several comments about the design of the HIMALAYA trial, which has a third treatment arm in which patients received durvalumab alone. El-Khoueiry noted that single-agent durvalumab was noninferior to sorafenib, but he added that no conclusions could be drawn about the STRIDE regimen in comparison with durvalumab as a single agent, because the trial was not powered for that.